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Abstract
Background: Moxibustion is a traditional Chinese method that uses the heat generated by burning herbal 
preparations containing Artemisia vulgaris to stimulate acupuncture points. Considering moxibustion is closely related 
to acupuncture, it seems pertinent to evaluate the effectiveness of moxibustion as a treatment of symptoms of cancer. 
The objective of this review was to systematically assess the effectiveness of moxibustion for supportive cancer care.
Methods: We searched the literature using 11 databases from their inceptions to February 2010, without language 
restrictions. We included randomised clinical trials (RCTs) in which moxibustion was employed as an adjuvant 
treatment for conventional medicine in patients with any type of cancer. The selection of studies, data extraction, and 
validations were performed independently by two reviewers.
Results: Five RCTs compared the effects of moxibustion with conventional therapy. Four RCTs failed to show 
favourable effects of moxibustion for response rate compared with chemotherapy (n = 229, RR, 1.04, 95% CI 0.94 to 
1.15, P = 0.43). Two RCTs assessed the occurrence of side effects of chemotherapy and showed favourable effects of 
moxibustion. A meta-analysis showed significant less frequency of nausea and vomiting from chemotherapy for 
moxibustion group (n = 80, RR, 0.38, 95% CIs 0.22 to 0.65, P = 0.0005, heterogeneity: χ2 = 0.18, P = 0.67, I2 = 0%).
Conclusion: The evidence is limited to suggest moxibustion is an effective supportive cancer care in nausea and 
vomiting. However, all studies have a high risk of bias so effectively there is not enough evidence to draw any 
conclusion. Further research is required to investigate whether there are specific benefits of moxibustion for supportive 
cancer care.
Background
Most cancer patients experience multiple symptoms
related to either the cancer itself or late treatment effects
[1]. The frequently experienced and severe adverse events
associated with such treatments lead patients to seek sup-
portive complementary and alternative medicine (CAM)
[2]. Most patients use CAM as an adjunct to conventional
treatments [3-5]. Acupuncture type interventions are one
of the most popular forms of CAM [6]. It is now a widely
accepted intervention for the treatment of a variety of
conditions [7]. Several reviews claim that acupuncture
offers therapeutic benefits for cancer patients [8-10].
Moxibustion is a traditional Chinese method that uses
the heat generated by burning herbal preparations con-
taining  Artemisia vulgaris to stimulate acupuncture
points [11]. There are two types of moxibustion. Direct
moxibustion is applied directly to the skin surface at the
acupuncture point [11]. In indirect moxibustion some
insulating materials (ginger, salts and etc) were placed
between the moxa cone and the skin [11]. Considering
moxibustion is closely related to acupuncture, it seems
pertinent to evaluate the effectiveness of moxibustion as
a treatment of symptoms of cancer. Several reviews of
moxibustion for cancer care are currently available [12-
16]. However, most of these review failed to employ sys-
tematic and transparent methods and are open to bias
[12,14-16]. Furthermore, they did not focus on moxbus-
tion and do not provide specific evidence for moxibustion
during cancer care. One overview [13], was not also com-
prehensive and open to selection bias. Currently, no sys-
tematic review of this subject is available. The aim of this
systematic review was to critically evaluate all of cur-
rently available randomised clinical trials regarding the
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effectiveness of any type of moxibustion as adjunct ther-
apy during cancer care.
Methods
Data sources
The following databases were searched from inception
through to February 2010: MEDLINE, EMBASE,
CINAHL, PychInfo, five Korean Medical Databases
(Korean Studies Information, DBPIA, Korea Institute of
Science and Technology Information, KoreaMed, and
Research Information Center for Health Database), Chi-
nese Medical Database (China National Knowledge
Infracture: CNKI), The Cochrane Library 2010, Issue 1
and Japan Science and Technology Information
Aggreator, Electronic (J-STAGE). The search terms were
used as follows: (moxibustion OR moxa*) AND (cancer
OR metasta$ OR carcinoma OR oncolo$ OR malignan$)
in Korean, Chinese, or English. Reference lists of all
obtained papers were searched in addition. We also per-
f o r m ed  e l ec t r o n i c  s e a r c h e s  o f  r e l ev a n t  j o u r n a l s  ( F A CT
[Focus on Alternative and Complementary Therapies],
and Research in Complementary Medicine [Forschende
Komplementarmedizin] up to January 2010) through
their website. Further, our own personal files were manu-
ally searched. Hardcopies of all articles were obtained and
read in full.
Study selection
Prospective randomised clinical trials (RCTs) were
included if moxibustion was used as the sole treatment or
as an adjunct to other treatments for patients having any
type of cancer (if the control group also received the same
concomitant treatments as the moxibustion group) and if
clinically relevant outcomes were assessed. Trials with
designs that did not allow an evaluation of efficacy of the
test intervention (eg, by using a treatments of unproven
efficacy in the control group or comparing two different
f o rm s  o f  m o x i b us t i o n )  w e r e  e x c l u d ed .  T ria l s  w e r e  a ls o
excluded if only immunological or biological parameters
were accessed. Trials published in the forms of disserta-
tion and abstract were included. No language restrictions
were imposed.
Data extraction and assessment of risk of bias
Hard copies of all articles were obtained and read in full.
All articles were read by three independent reviewers
(MSL, TYC, SSL) and data from the articles were vali-
dated and extracted according to pre-defined criteria
(Table 1). No language limitations were imposed.
Risk of bias was assessed using the Cochrane classifica-
tion in four criteria: sequence generation, blinding,
incomplete outcome measures, and allocation conceal-
ment [17]. Considering that it is hard to blind therapists
to the use of moxibustion, we assessed patient and asses-
sor blind separately. If it is patient-assessed pain then it is
not possible to assessor blind because the patient himself
would be the assessor. The assessor needs to be a differ-
ent person. Thus, if pain is assessed by another person
(not the patient himself) then assessor blinding would be
possible. Disagreements were resolved by discussion
between the two reviewers (MSL, TYC). There were no
disagreements between the three reviews about the risk
of bias.
Data synthesis
To summarise the effects of moxibustion on outcomes
(response rate), we abstracted the risk estimates (relative
risk: RR) and and 95% confidence interval (CI) was calcu-
lated using the Cochrane Collaboration's software
(Review Manager (RevMan) Version 5.0 for Windows.
Copenhagen: The Nordic Cochrane Centre). For studies
with insufficient information, we contacted the primary
authors to acquire and verify data where possible. If
appropriate, we then pooled the data across studies using
random effects models (if excessive statistical heteroge-
neity did not exist). The chi-square test, and the Higgins
I2 test were used to assess heterogeneity.
Results
Study description
The searches identified 515 potentially relevant articles of
which 510 studies were excluded (Figure 1). Key data of
the included 5 RCTs are summarized in Table 1[18-22].
All trials originated from China. Three [18,19,22] of the
included trials had a two-armed, parallel group design
and two RCTs [20,21] used a 3-armed parallel group
design. The types of cancer treated within the trials were
gastric cancer [20], nasopharyngeal carcinoma [18,19],
and various cancers [21,22]. The objective outcome mea-
sures were survival rate [19], response rate [18-21], and
side effects of chemotherapy [19,20], and quality of life
[21,22]. None of the included RCTs reported the rationale
for selecting treatment points. All RCTs employed indi-
rect moxibustion.
Risk of bias
The most of included trials had high risk of bias. One
RCT [19] employed appropriate sequence generation.
None described incomplete outcome measures One
study reported details about allocation concealment [19].
None assessed the adverse events from moxibustion.
Outcomes
Response rate
Four RCTs reported response rate for moxibustion as an
adjunctive of chemotherapy compared with chemother-
apy [18-21]. All of 4 RCTs failed to show favourable
effects of moxibustion on response rate. The meta-analy-L
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Table 1: Summary of parallel open, randomised clinical studies of moxibustion for cancer
First author (year) Sample size
Condition
Intervention group (Regimen) Control group
(Regimen)
Main outcomes Intergroup differences Treated acupuncture 
points
Rationale for point 
selection
Cheng (2005) [18] 84
Nasopharyngeal 
carcinoma
(A) Moxibustion (once daily for 30 
days, n = 42), plus radiotherapy and 
chemotherapy
Indirect
(B) Chemotherapy and 
radiotherapy, plus drug 
therapies for side effects 
(n = 42)
Response rate NS, 1.05 [0.95, 1.16] CV8
n.r.
Chen (2000) [19] 56
Nasopharyngeal 
carcinoma
(A) Moxibustion (once daily for 30 
days, n = 28), plus (B)
Indirect
(B) Chemotherapy and 
radiotherapy (n = 28), 
plus drug therapies for 
side effects
1) Response rate
2) Side effect of 
chemotherapy3) 5-year 
survival rate
1) NS, 1.10 [0.83, 1.44]
2) P < 0.05 in favour of A
3) NS, 1.40 [0.75, 2.60]
CV8
n.r.
Cao (1997) [20] 36
Gastric cancer
(A) Moxibustion (3 times weekly, 
n.r, n = 12), plus (B)
Indirect
(B) Chemotherapy(n = 12)
(C) Chemotherapy plus 
drug therapies for side 
effects (n = 12)
1) Response rate
2) Side effect of 
chemotherapy
1) NS, 2.0 [0.82, 2.34]
2) P < 0.05 in favour of A
CV8
n.r.
Liu (2001) [21] 81
Various cancer
(Malignant tumor)
(A) Moxibustion (once daily, n.r, n = 
30), plus (B)
Indirect
(B) Chemotherapy (n = 
35), plus herbal medicine 
(Gubenyiliu III 400 ml, 
twice a day)
(C) Chemotherapy (n = 16)
1) Response rate
2) Living quality
1) NS, 0.99 [0.87, 1.12]
2) NS, 0.22 [-0.27, 0.71]
GV14, BL17, ST36
n.r.
Bian (2004) [22] 44
Various cancer (cancer 
pain)
(A) Moxibustion (2-3 times daily for 
20 days, n = 23), plus morphine 
injection (acupoint, 5-10 mg, twice 
a day)
Indirect
(B) Morphine injection 
(10-20 mg, 2-3 times a 
day, n = 21)
Living quality P < 0.00001, 2.03 [1.29, 
2.78] in favour of A
GV14, CV4, ST36, LI4, ashi-
point
n.r.
NS: not significant; n.r.: not reportedLee et al. BMC Cancer 2010, 10:130
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Figure 1 Flowchart of trial selection process. RCT: randomized clinical trial; CCT: controlled clinical trial; UOSs: uncontrolled observational studyLee et al. BMC Cancer 2010, 10:130
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sis also suggested not significant difference between two
groups (n = 229, RR, 1.04, 95% CI 0.94 to 1.15, P = 0.43,
heterogeneity: χ2 = 4.06, P = 0.26, I2 = 26%, Figure 2A).
Subanalysis also failed to show favourable effects of mox-
ibustion on response rate in patients with nasopharyn-
geal carcinoma (n = 140, RR, 1.06, 95% CIs 0.96 to 1.16, P
= 0.24, heterogeneity: χ2 = 0.12, P = 0.73, I2 = 0%, Figure
2A) [18,19].
Side effect of chemotherapy
Two RCTs assessed the occurrence of side effects of che-
motherapy [19,20]. Both studies showed favourable
effects of moxibustion plus chemotherapy compared with
chemotherapy. A meta-analysis showed significant less
frequency of nausea and vomiting from chemotherapy for
moxibustion group (n = 80, RR, 0.38, 95% CIs 0.22 to
0.65, P = 0.0005, heterogeneity: χ2 = 0.18, P = 0.67, I2 = 0%,
Figure 2B).
Quality of life
Two RCTs tested the effects moxibustion on quality of life
compared with chemotherapy or morphine injection
[21,22]. One RCT [22] showed favourable effects of moxi-
bustion compared with morphine injection, while other
RCT [21] failed to generate positive effects compared
with chemotherapy.
Discussion
This systematic review identified only very few RCTs for
moxibustion. Their results fail to provide convincing evi-
dence for the effectiveness of moxibustion. However, two
RCTs demonstrate that moxibution as an adjunctive ther-
apy is more effective for reduction of side effects (from
chemotherapy) than chemotherapy alone [19,20], specifi-
cally for nausea and vomiting. In the present set of stud-
ies, an absence of adequate statistical analysis of the
variability of therapeutic protocols and poor quality of
reporting are frequent methodological problems. Collec-
tively, the current evidence from RCTs of moxibustion as
supportive cancer care is not convincing. However, the
number of trials and the total sample size and their meth-
odological quality are too low to draw firm conclusions.
Figure 2 A forest plot of moxibustion for cancer care. (A) treating cancer, showing the response rate for moxibustion plus chemotherapy vs. che-
motherapy; (B) side effects.Lee et al. BMC Cancer 2010, 10:130
http://www.biomedcentral.com/1471-2407/10/130
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The risk of bias in the studies was assessed based on the
descriptions of sequence generation, blinding, incom-
plete outcome data, and allocation concealment. All of
the studies were burdened with a high risk of bias. One
RCT [19] employed allocation concealment and none of
the RCTs made an attempt to blind assessors. One RCT
[19] reported details of drop-outs and withdrawals, while
the others didn't describe that may have led to exclusion
or attrition biases. Thus the reliability of the evidence
presented is clearly limited.
All of included trials c om par ed indirect mo xibustion
with chemotherapy or morphine. The fact that there is no
good trial evidence in support of moxibustion is in line
with several different interpretations. Moxibustion may
be ineffective, the studies may have been incorrectly
designed or the treatment may not have been adminis-
tered optimally in the existing studies. In the absence of a
sufficient number of RCTs, other types of evidence might
be helpful. Two controlled trials reported positive effects
of moxibustion compared with chemotherapy, drug or no
treatment in cancer patients [23,24]. Uncontrolled trials
also imply that moxibustion is beneficial for symptom
management of various cancers [25-29]. Unfortunately,
such data are highly susceptible to bias and hence, they
provide little useful information on the specific effects of
moxibustion as it relates to supportive cancer care.
One argument for using moxubustion for the support-
i ve  ca r e  f or  canc e r m igh t  be  t ha t  it  is  sa f e r t ha n dru g
treatment. None of included trials assessed adverse
events. Currently 3 studies evaluated the adverse events
or possible risks of moxibution [30-32]. Mild or no
adverse effects of were noted in previous reports [30,32],
while one study [31] concerned possible hazardous in
health by smoke from mouldering moxibustion. Relative
to those of other conventional treatments, these are mild,
infrequent and perhaps even negligible. Further study is
needed to clarify this.
Assuming that moxibustuon is beneficial for cancer
patients, possible mechanisms of action are of interest.
Moxibustion may exert not only absorption of extract
from moxa on acupuncture points but also direct effects
due to acupuncture point stimulation from heat. Some
aspect of mechanism may be similar that of acupuncture.
One of them is that moxibustion may influence the multi-
ple cortical, subcortical/limbic, and brainstem areas [33-
37]. Involving these modulation therapeutic effects of
moxibustion may mediate partially through opioidergic
and/or monoaminergic neurotransmission [35,38]. Acu-
puncture often evokes complex somatosensory sensa-
tions and may modulate the cognitive/affective
perception of pain, suggesting that many effects are sup-
ported by the brain and extending central nervous system
networks [36,39,40]. Another possible mechanism
includes an influence on the heat shock proteins and the
function of immune cells. It has been shown that moxi-
bustion up-regulated heat shock protein 70 and
decreased the gastric injury and apoptosis of gastric
mucosal cells [41]. The third hypothesis is that the moxi-
bustion improves the function of immune cells. Moxibus-
tion induced higher cellular immune function and
increased the content of β-endorphin in the lymphocyte
of the spleen in HAC cancer mice [42]. Moxibustion may
modulate immunity through neurohormonal regulatory
mechanism. Moxibustion also inhibited the growth of
tumor and enhanced cellular immune functions via
cytokine production (IL-2 or IL-12) [43] and increase of
natural killer cell activity in tumor-bearing mice [44].
None of these theories are, however, currently fully estab-
lished.
One could also argue about the value of conducting sys-
tematic reviews or meta-analyses of a limited number of
included studies. They can increase power, improve pre-
cision, answer questions not asked by individual studies,
settle controversies arising from conflicting results,
improve the quality of future primary studies, and gener-
ate new hypotheses [45-47]. Systematic review can also
avoid biases and make results and conclusions as objec-
tive as possible [46]. Even systematic reviews that find no
primary studies to include can be valuable in that they
may point towards important gaps in our knowledge.
However, systematic reviews are retrospective and
strongly depend on the quality of the primary studies
[46]. They may also lead to contradictory overall conclu-
sions [46]. The use of statistics does not guarantee that
the results are valid. In our case, as the conclusions from
the meta-analyses are from only 4 RCTs, the conclusions
must remain tentative.
Limitations of our systematic review pertain to the
potential incompleteness of the evidence reviewed. We
aimed to identify all studies on the topic. The distorting
effects of publication bias and location bias on systematic
reviews are well documented [48-50]. In the present
review there were no restrictions on the review publica-
tion language, and a large number of different databases
were searched. We are therefore confident that our
search strategy located all relevant data on the subject.
Most of the included RCTs that reported positive results
come from China, a country which has been shown to
produce no negative results [51]. Further limitations
include the paucity and the often suboptimal quality of
the primary data.
Conclusion
The evidence is limited to suggest moxibustion is an
effective supportive cancer care in nausea and vomiting.
However, all studies have a high risk of bias so effectively
there is not enough evidence to draw any conclusion. Fur-
ther research is required to investigate whether there areLee et al. BMC Cancer 2010, 10:130
http://www.biomedcentral.com/1471-2407/10/130
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specific benefits of moxibustion for supportive cancer
care.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MSL conceived the study design. TYL, and JEP searched and selected the trials,
extracted, analyzed and interpreted the data. MSL drafted the manuscript. TYC
and SSL searched Chinese Databases and extract data from Chinese literatures.
TYC updated the search and the content of the review. EE helped with the
study design and critically reviewed the manuscript. All authors read and
approved the final version of the manuscript.
Acknowledgements
MSL, TYC, JEP and SSL were supported by the Korea Institute of Oriental Medi-
cine.
Author Details
1Division of Standard Research, Korea Institute of Oriental Medicine, Daejeon, 
South Korea and 2Complementary Medicine, Peninsula Medical School, 
Universities of Exeter & Plymouth, Exeter, UK
References
1. Wong R, Sagar CM, Sagar SM: Integration of Chinese medicine into 
supportive cancer care: a modern role for an ancient tradition.  Cancer 
Treat Rev 2001, 27:235-246.
2. National Center for Complementary and Alternative Medicine: Cancer 
and complementary and alternative medicine.   [http://nccam.nih.gov/
health/cancer/camcancer.htm]. Accessed at 31 March 2010
3. Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA: 
Complementary and alternative medicine use by patients enrolled 
onto phase I clinical trials.  J Clin Oncol 2004, 22:4810-4815.
4. Frenkel M, Ben-Arye E, Baldwin CD, Sierpina V: Approach to 
communicating with patients about the use of nutritional 
supplements in cancer care.  South Med J 2005, 98:289-294.
5. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE: 
Complementary/alternative medicine use in a comprehensive cancer 
center and the implications for oncology.  J Clin Oncol 2000, 
18:2505-2514.
6. Barnes PM, Bloom B, Nahin R: Complementary and alternative medicine 
use among adults and children: United States, 2007.  CDC National 
Health Statistics Report #12  [http://nccam.nih.gov/news/2008/nhsr12.pdf]. 
Accessed at 31 March 2010.
7. Ernst E: Acupuncture--a critical analysis.  J Intern Med 2006, 259:125-137.
8. Deng G, Vickers A, Simon Yeung K, Cassileth BR: Acupuncture: 
integration into cancer care.  J Soc Integr Oncol 2006, 4:86-92.
9. Ernst E, Pittler M, Wider B, Boddy K: Oxford Handbook of Complementary 
Medicine Oxford, UK: Oxford University Press; 2008. 
10. Lao L: Acupuncture practice, past and present: is it safe and effective?  J 
Soc Integr Oncol 2006, 4:13-15.
11. World Health Organization Western Pacific Region: WHO International 
Standard Terminologies on Traditional Medicine in the Western Pacific 
Region.  Manila, Philippine: World Health Organization Western Pacific; 
2007:251-254. 
12. Chen ZJ, Guo YP, Wu ZC: Advances of clinical study on acupuncture and 
moxibustion for treatment of cancer pain.  Chin Acupunct Moxibustion 
2008, 28:392-394.
13. Kim SY, Chae Y, Lee SM, Lee H, Park HJ: The effectiveness of moxibustion: 
an overview during 10 years.  Evid Based Complement Alternat Med 2009 
in press.
14. Kuai L, Chen H, Yang HY: Current status and prospect of acupuncture-
moxibustion in treatment of cancer pain: a review.  Zhong Xi Yi Jie He 
Xue Bao 2008, 6:197-202.
15. Shen QP, Tian HQ: Acupuncture-moxibustion in treatment of cancer 
pain:a review.  Henan Tradit Chin Med 2008, 28:84-86.
16. Zhang JL, Li SS, Luo WH, Zhang DF, Shu RG: Research of moxibustion 
therapy for cancer:a review.  Jiangxi J Tradit Chin Med 2008, 39:59-61.
17. Higgins JPT, Altman DG: Assessing risk of bias in included studies.  In 
Cochrane Handbook for Systematic Reviews of Interventions Edited by: 
Higgins JPT, Green S. West Sussex, England: Wiley-Blackwell; 
2008:187-241. 
18. Cheng Z, Jiang Y, Chen K: Radiochemical and chemotherapy therapy 
with Shenque Point moxibustion treatment of 42 cases of advanced 
nasopharyngeal carcinoma.  New J Tradit Chin Med 2005, 37:58-59.
19. Chen K, Jiang Y, Wen H, Lu XZ, Lu L, Wang H, Huang GZ: Clinical study on 
treatment of nasopharyngeal carcinoma by radio and chemotherapy 
with supplementary moxibustion on Shenque point.  Chin J Integ Med 
2000, 20:733-735.
20. Cao JX, Xiao XH, Tang XY: Elemene fluorouracil Moxibustion "Shenque" 
effect in the treatment of advanced gastric cancer observed.  Chin J Clin 
Oncol 1997, 24:549-550.
21. Liu J, Yu RC, Rao XQ: Study on Effect of Moxibustion and Guben Yiliu ¥2 
Combined with Chemotherapy in Treating Middle-Late Stage 
Malignant Tumor.  Chin J Integr Tradit West Med 2001, 21:262-264.
22. Bian D, Cheng ZD, Zhang NS, et al.: Effects of Acupoint-injection plus 
moxibustion on IL-2/IL-2R expression in peripheral blood in the patient 
with carcinous pain.  Chin Acupunct Moxibustion 2004, 24:641-644.
23. Deng H, Long SQ, Wu WY, et al.: Prevention and treatment of leucopenia 
due to chemotherapy by moxibustion:A clinical observation of 46 
cases.  J New Chin Med 2007, 39:90-91.
24. Huang XM: Acupuncture and moxa cone moxibustion treatment of 
chemotherapy-induced diarrhea in 70 cases.  Henan Tradit Chin Med 
1996, 16:173.
25. Huang XM, Chen HL, Guo XM, Ma YM: Treatment with cone moxibustion 
of chemotherapeutic leucocytopenia in 114 cases.  J Tradit Chin Med 
1993, 13:266-267.
26. Wang CP: Ginger-partitioned moxibustion back yu point for treatment 
of luekopenia induced by chemotherapy clinical observation of 40 
cases.  Hebei J radit Chin Med 2008, 30:412.
27. Wang LS, Wang LZ, Chen YR: Ginger-partitioned moxibustion treatment 
of chemotherapy response in patients with gastrointestinal Clinical 
observation and nursing care.  Chin J Nurs 1990:335-336.
28. Yao X, Miao N: Effect of ginger-partition moxibustion combining 
acupoint injection to chemotherapy-vomit.  Jilin Med J 2007, 
28:1681-1682.
29. Zhai DD, Chen HP, Wang RZ, Ding BY: Moxibustion directly regulate 
cellular immune function in patients with cancer of the observation.  J 
Cliin Acupunct Moxibustion 1994, 10:25-27.
30. Guittier MJ, Klein TJ, Dong H, Andreoli N, Irion O, Boulvain M: Side-effects 
of moxibustion for cephalic version of breech presentation.  J Altern 
Complement Med 2008, 14:1231-1233.
31. Wheeler J, Coppock B, Chen C: Does the burning of moxa (Artemisia 
vulgaris) in traditional Chinese medicine constitute a health hazard?  
Acupunct Med 2009, 27:16-20.
32. Yamashita H, Tsukayama H, Tanno Y, Nishijo K: Adverse events in 
acupuncture and moxibustion treatment: a six-year survey at a 
national clinic in Japan.  J Altern Complement Med 1999, 5:229-236.
33. Hui KK, Liu J, Makris N, Gollub RL, Chen AJ, Moore CI, Kennedy DN, Rosen 
BR, Kwong KK: Acupuncture modulates the limbic system and 
subcortical gray structures of the human brain: evidence from fMRI 
studies in normal subjects.  Hum Brain Mapp 2000, 9:13-25.
34. Hui KK, Liu J, Marina O, Napadow V, Haselgrove C, Kwong KK, Kennedy DN, 
Makris N: The integrated response of the human cerebro-cerebellar 
and limbic systems to acupuncture stimulation at ST 36 as evidenced 
by fMRI.  Neuroimage 2005, 27:479-496.
35. Lu W, Dean-Clower E, Doherty-Gilman A, Rosenthal DS: The value of 
acupuncture in cancer care.  Hematol Oncol Clin North Am 2008, 
22:631-648.
36. Napadow V, Ahn A, Longhurst J, Lao L, Stener-Victorin E, Harris R, Langevin 
HM: The status and future of acupuncture mechanism research.  J 
Altern Complement Med 2008, 14:861-869.
37. Napadow V, Makris N, Liu J, Kettner NW, Kwong KK, Hui KK: Effects of 
electroacupuncture versus manual acupuncture on the human brain 
as measured by fMRI.  Hum Brain Mapp 2005, 24:193-205.
38. Han JS: Acupuncture: neuropeptide release produced by electrical 
stimulation of different frequencies.  Trends Neurosci 2003, 26:17-22.
39. Dhond RP, Kettner N, Napadow V: Neuroimaging acupuncture effects in 
the human brain.  J Altern Complement Med 2007, 13:603-616.
Received: 7 November 2009 Accepted: 7 April 2010 
Published: 7 April 2010
This article is available from: http://www.biomedcentral.com/1471-2407/10/130 © 2010 Lee et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Cancer 2010, 10:130Lee et al. BMC Cancer 2010, 10:130
http://www.biomedcentral.com/1471-2407/10/130
Page 8 of 8
40. Mao JJ, Kapur R: Acupuncture in Primary Care.  Prim Care 2010, 
37:105-117.
41. Yi SX, Peng Y, Chang XR, Peng N, Yan J, Lin YP: Effect of pre-moxibustion 
on apoptosis and proliferation of gastric mucosa cells.  World J 
Gastroenterol 2007, 13:2174-2178.
42. Zhang ZI, Chen JI, Zhu SL: Endorphin mechanism of the regulating 
effect of direct moxibustion on immunity.  Shanghai J Acupunct 
Moxibustion 13:223-224.
43. Pei J: Effect of moxibustion of dazhui (GV-14) on cellular immune 
function in tumor-bearing mice.  Int J Orient Med 1995, 20:72-76.
44. Qiu X, Chen K, Tong L, Shu X, Lu X, Wen H, Deng C: Effects of moxibustion 
at shenque (CV 8) on serum IL-12 level and NK cell activities in mice 
with transplanted tumor.  J Tradit Chin Med 2004, 24:56-58.
45. Mullen PD, Ramirez G: The promise and pitfalls of systematic reviews.  
Annu Rev Public Health 2006, 27:81-102.
46. Linde K, Willich SN: How objective are systematic reviews? Differences 
between reviews on complementary medicine.  J R Soc Med 2003, 
96:17-22.
47. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of 
Interventions West Sussex, England: Wiley-Blackwell; 2008. 
48. Ernst E, Pittler MH: Alternative therapy bias.  Nature 1997, 385:480.
49. Pittler MH, Abbot NC, Harkness EF, Ernst E: Location bias in controlled 
clinical trials of complementary/alternative therapies.  J Clin Epidemiol 
2000, 53:485-489.
50. Rothstein HR, Sutton AJ, Borenstein M: Publication bias in meta-analysis.  
In Publication bias in meta-analysis Edited by: Rothstein HR, Sutton AJ, 
Borenstein M. Chichester, West Sussex: Wiley; 2005. 
51. Vickers A, Goyal N, Harland R, Rees R: Do certain countries produce only 
positive results? A systematic review of controlled trials.  Control Clin 
Trials 1998, 19:159-166.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/130/prepub
doi: 10.1186/1471-2407-10-130
Cite this article as: Lee et al., Moxibustion for cancer care: a systematic 
review and meta-analysis BMC Cancer 2010, 10:130